Abstract-Activation of the intrinsic pathway of coagulation contributes to the pathogenesis of arterial and venous thrombosis.
T he vertebrate coagulation system is essential for the maintenance of a closed high-pressure circulatory system. 1 Appropriate activation of coagulation in response to vascular injury is required for effective hemostasis that facilitates the cessation of bleeding. Primary hemostasis is initiated by accumulation and activation of platelets at the site of vascular injury. 2 During secondary hemostasis, activation of coagulation reinforces the platelet plug through deposition of an insoluble fibrin network. 2 Aberrant activation of coagulation can, however, lead to the formation of intravascular clots that underpin pathological thrombotic disorders, including myocardial infarction, stroke, and venous thromboembolism. There are 2 primary pathways for the initiation of coagulation that converge at FX (factor X; Figure) . In the extrinsic pathway exposure of subendothelial TF (tissue factor) complexed with activated FVII, known as the extrinsic Xase, catalyzes the generation of FXa (activated FX). 4 In the intrinsic pathway initially described by Davie and Ratnoff 5 and MacFarlane, 6 a waterfall-based model involving the sequential activation of FXII, FXI, and FIX leads to formation of the intrinsic Xase, a complex of FVIIIa (activated factor VIII) and FIXa (activated factor IX), that also catalyzes the generation of FXa. FXa in complex with its cofactor FVa forms the prothrombinase complex that catalyzes the cleavage of prothrombin (FII) to thrombin (FIIa). Thrombin as the terminal coagulation protease catalyzes the formation of insoluble fibrin through cleavage of soluble fibrinogen monomers and activation of the transglutaminase FXIII ( Figure) . In addition, thrombin is a potent activator of platelets through cleavage of cell surface protease-activated receptors.
In this review, we discuss the involvement of intrinsic pathway activation in the pathogenesis of thrombosis with a particular focus on insights gained from animal models. We further elaborate on the development of intrinsic pathway inhibitors and their potential utility as antithrombotic agents.
Regulation of Intrinsic Pathway Activation
FXII can readily be activated by exposure to negatively charged molecules and surfaces. Early studies revealed that incubation of FXII with negatively charged molecules, including dextran sulfate and silica, was sufficient to induce autoactivation. [7] [8] [9] More recently, a number of physiological surfaces have been identified that mediate autoactivation of FXII, including RNA, DNA, and polyphosphate. [10] [11] [12] [13] It is interesting to consider, however, if other sources of negative surface, such as the plasma membrane of activated platelets, could also provide an abundant surface for FXII autoactivation. 14 In addition to serving as a critical component of the intrinsic pathway, FXII is also a central component of the contact system that includes PKK (prekallikrein) and HK (high molecular weight kininogen). Activation of the intrinsic pathway can be enhanced by the actions of both PKK and HK. During the process of contact activation, initially generated FXIIa can activate PKK forming αKK (α-kallikrein) that can itself activate FXII establishing a positive feedback loop. Critically, αKK mediated activation of FXII is ≈30× more efficient than autoactivation of FXII on a negative surface. 7 The reciprocal activation of FXII and PKK is further amplified through the cofactor activity of HK. 15, 16 Interestingly, single chain FXII zymogen that has not undergone limited proteolysis, possesses low proteolytic activity and can activate PKK in a process that is enhanced by polyphosphate. 17, 18 The intrinsic pathway can also be activated by components of the extrinsic and common pathways. Cross-activation is thought to be important for the sustained activation of coagulation as activity of the TF;FVIIa complex is inhibited by tissue factor pathway inhibitor. 19 The work of Josso and others described the capacity of the TF;FVIIa complex to efficiently activate FIX. 20, 21 Consistent with the importance of this pathway in the activation of the clotting cascade, a mutation in FIX that limits activation by TF;FVIIa, but not FXIa, is associated with a mild form of hemophilia. 22 More recently, it has been shown that the TF;FVIIa and TF;FVIIa;FXa complexes can also activate FVIII. 23, 24 Through this mechanism, the extrinsic Xase, TF;FVIIa, and product FXa can directly promote formation of the active intrinsic Xase, FVIIIa;FIXa. The work of Gailani and others has revealed that the terminal coagulation protease thrombin can also feedback activate FXI leading to a marked amplification of thrombin generation. [25] [26] [27] Interestingly, polyphosphate strongly enhances thrombinmediated activation of FXI. 28 It has, however, been reported that the major physiological target of thrombin, fibrinogen, may limit the ability of thrombin to activate FXI in plasmabased systems. 29, 30 Although described extensively in vitro, it remains to be determined if TF:FVIIa-mediated activation of FIX, TF;FVIIa;FXa mediated activation of FVIII, and thrombin-mediated activation of FXI play important physiological roles in vivo.
Arterial Thrombosis in Animal Models
Studies of different gene-specific knockout mice have provided considerable insight into the contribution of intrinsic pathway activation to arterial thrombosis ( Table 1) . Deletion of FIX in mice was found to reduce arterial thrombus formation in the carotid artery ferric chloride model but was associated with markedly increased bleeding consistent with the phenotype of patients with hemophilia B.
32 FXI-deficient mice were protected from arterial thrombosis in the carotid artery ferric chloride model without altering tail bleeding times. 32, 34 Interestingly, FXI deficiency did not confer protection from arterial thrombosis in a mouse ear laser injury model. 34 Loss of FXII provided protection against thrombosis in both mesenteric artery and carotid artery ferric chloride models of thrombosis. 33, [37] [38] [39] In addition, rats deficient for FXII are also protected against thrombosis in the carotid artery ferric chloride model. 38 Importantly, FXII knockouts do not have prolonged bleeding times in the tail transection or cuticle bleeding models. 37, 38 Components of the contact system that contribute to the activation of FXII also have phenotypes in models of arterial thrombosis. Deletion of the Kng1 gene, required for plasma borne HK, was associated with reduced thrombus formation in the carotid artery Rose Bengal light-dye injury model of thrombosis. 42 Similarly, PKK-deficient mice had reduced thrombus formation in both the carotid artery ferric chloride and Rose Bengal light-dye injury models. 40, 41 Although PKK serves as an important activator of FXII, studies of PKK-deficient mice indicate that there may be other FXIIindependent contributions of PKK to arterial thrombosis. 41 Deletion of PKK was found to suppress bradykinin signaling, which resulted in compensatory upregulation of Mas receptor expression that under conditions of normal levels of angiotensin II lead to increased prostacyclin generation. 41 Prostacyclin exhibits direct antithrombotic effects acting as a potent inhibitor of platelet aggregation and indirect effects through Sirtuin 1 and Kruppel-like factor 4 dependent suppression of TF expression. 41, 43, 44 It has proven challenging to compare results between intrinsic pathway knockouts due to the differing models and conditions used to initiate arterial thrombosis. Importantly, comprehensive assessments of intrinsic pathway knockouts have been conducted in the carotid artery ferric chloride model in which vascular injury was initiated using a range of ferric chloride concentrations. 33 ,39 Interestingly, a moderately stronger level of thromboprotection was observed in FXII-deficient mice than either FXI-or FIX-deficient mice. 33 These findings suggest that there may be FIX and FXI-independent functions of FXII. A stronger level of thromboprotection was also observed in FXIIdeficient mice when compared with PPK-and HK-deficient mice. 39 This data suggests that PPK independent FXII autoactivation occurs during arterial thrombosis and that PPK and HK likely support further FXIIa generation. These findings are also consistent with the differential prolongation of activated partial thromboplastin times observed in patients with congenital intrinsic pathway deficiencies. A deficiency of FXII is associated with longer prolongation of activated partial thromboplastin time (aPTT) than that for FXI or PKK deficiency.
The observed protection of intrinsic pathway knockouts from arterial thrombosis has led to the evaluation of numerous inhibitors of this pathway in models of thrombosis (Table 2) . A variety of inhibitory strategies have been used, including function-blocking antibodies, antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), and small molecules. The anti-FXI antibody 14E11 that selectively prevents activation of FXI by FXIIa, but not thrombin, inhibited thrombus formation in the carotid artery ferric chloride model providing and almost equivalent strength of phenotype as FXI-deficient mice. 33 This finding suggests that FXIIa is the primary driver of FXI activation. More recently, the anti-FXIa antibody C24 was found to dose-dependently inhibit thrombus formation in the carotid artery ferric chloride model. 47 The antithrombotic potential of a number of FXII-targeting antibodies has also been assessed. The anti-FXII antibodies 15H8 and 9A2 inhibited thrombus formation in the carotid ferric chloride model. 53 Additionally, an antibody that binds specifically to FXIIa, but not FXII, 3F7, inhibited thrombus formation in the carotid artery ferric chloride model. 54 Nucleotide-based gene silencing therapies have also been developed against components of the intrinsic pathway. Administration of FIX-targeted siRNA at doses that reduced FIX activity by ≈90% inhibited arterial thrombosis in a rat carotid artery ferric chloride. 45 Surprisingly, siRNA-mediated FIX gene knockdown was not associated with increased bleeding suggesting a differential threshold in the amount of FIX required to promote hemostasis versus thrombosis. 45 A FXI-targeting ASO administered at a dose that reduced FXI activity by ≈80% reduced thrombosis in an aortic ferric chloride model. 51 Similarly, ASOs against FXII and PKK that reduced levels of their respective target proteins by ≈80% also inhibited thrombosis formation in a mesenteric arteriole ferric chloride model. 52 Interestingly, the antithrombotic effect of FXII-targeted ASO was maintained at lower doses than for PKK-targeted ASO. 52 This finding is consistent with the observation that FXII knockouts demonstrate more robust protection than PKK knockouts in the carotid artery ferric chloride model. 39 Complementary findings have been made with FXIItargeting siRNA administration resulting in a dose-dependent reduction in thrombus formation in a rat carotid artery ferric chloride model. 38 Although a mild prolongation in cuticle bleeding time was observed after FXII knockdown off-target effects of the FXII-targeting siRNA could not be excluded. 38 A small molecule irreversible inhibitor of FXIa, BMS-262084, reduced thrombus formation in a rat carotid artery ferric chloride model and a rabbit carotid artery electrolytic injury model. 48, 49 Likewise, a small molecule reversible and competitive inhibitor of FXIa, BMS-654457, also inhibited thrombus formation in the rabbit carotid artery electrolytic injury model in a dose-dependent manner. 50 Although other FXI small molecule inhibitors have been developed, the in vivo antithrombotic effects of these agents have not yet been reported. 61 A small peptide-based inhibitor of FXIIa, PhePro-Arg-chloromethylketone, reduced thrombus formation in the carotid ferric chloride model. 12 A protein-based FXIIa inhibitor has also been developed from the fourth domain of the hematophagus insect Triatoma infestans protein infestin, named infestin 4. 62 An albumin conjugated derivative of infestin 4, rHA-infestin 4 (recombinant human albumin conjugated infestin 4), inhibited thrombus formation in the carotid 37 Cai et al, 38 Cheng et al, 33 Kokoye artery, femoral artery, and mesenteric arteriole ferric chloride models. [55] [56] [57] It is important to note that rHA-infestin 4 inhibits plasmin and FXa activity at higher concentrations. 63 The effects of intrinsic pathway inhibition have also been explored in a model that more closely resembles human atherothrombotic disease. In this model, plaques in the carotid artery of western diet treated Apoe -−/− mice are physically disrupted by ultrasound and the resultant thrombus formation monitored by intravital fluorescence video microscopy. 64 In this model, inhibition of FXIIa by administration of corn trypsin inhibitor, a FXIIa inhibitor purified from Indiana sweet corn, or rHA-infestin 4 reduced accumulation of platelets at the site of plaque disruption. 58 Similarly, gene-mediated silencing of FXI expression by targeted ASOs resulted in a modest but significant attenuation in the accumulation of platelets and fibrin at the site of plaque disruption. 59 Several studies have also explored the contribution of intrinsic pathway activation to the thromboinflammatory response evoked by ischemia reperfusion injury. PKK, FXII, and FXI knockout mice demonstrated reduced cerebral infarction in a transient midcerebral artery occlusion stroke model. 65, 66 In this same model, inhibition of FXII with PhePro-Arg-chloromethylketone or rHA-infestin 4 and FXII mediated activation of FXI with the 14E11 antibody protecting against cerebral infarction.
65,67,68 In a murine microembolic injection stroke model inhibition of FXII with rHA-infestin 4 Barberry et al, 56 May et al, 57 also reduced the severity of cerebral infarction. 69 Inhibition of the intrinsic pathway was consistently associated with reduced fibrin deposition in infarcted regions of the brain suggesting that the antithrombotic potential of these agents may contribute to the observed phenotype; however, anti-inflammatory effects cannot be discounted. Indeed, PKK knockouts demonstrated reduced expression of the inflammatory cytokine IL (interleukin) 1β in the cortex and basal ganglia after transient midcerebral artery occlusion. 66 Findings made with intrinsic pathway inhibitors provide important complementary evidence to those made using gene knockout mice. It is possible that constitutive gene deletion may provide a strong selective drive for compensatory changes that could mask the phenotype of intrinsic pathway knockouts. However, the strong agreement between these 2 approaches in models of arterial thrombosis suggests that the effect of gene compensation is limited.
Venous Thrombosis in Animal Models
Studies of intrinsic pathway knockout mice indicate that this pathway also plays a major role in the formation of thrombi in the venous system (Table 1) . FVIII-deficient mice were found to be completely protected from venous thrombosis in the St Thomas' model. 31 In the St Thomas' model, a combination of reduced flow and endothelial injury are used to initiate thrombus formation in the infrarenal inferior vena cava (IVC). 31 Deletion of FXI resulted in reduced thrombus formation in the IVC ferric chloride model. 35 Interestingly, at low doses of ferric chloride, a more robust inhibition of thrombus formation was observed in FXI-deficient mice than therapeutic doses of heparin, clopidogrel, and agatroban. 35 Mice deficient for FXII demonstrated reduced thrombus burden in the IVC stenosis model. 36 Thrombus formation in the IVC stenosis model is induced by reduced flow in the absence of additional thrombotic stimuli. Surprisingly, in the same study, no significant reduction in thrombus burden was observed in FXI-deficient mice, suggesting a potential FXIindependent function of FXII in venous thrombosis. 36 This finding is consistent with observations made in the carotid artery ferric chloride model. 33 Interestingly, the fibrin density of thrombi from FXII-deficient mice was significantly lower than thrombi from controls. 36 FXII binds directly to fibrinogen and increases fibrin network density independent of thrombin generation providing a potential FXI-independent procoagulant function of FXII. 70 In line with the role of PKK in the activation of FXII, Klkb1 knockout mice also demonstrated reduced venous thrombosis in the IVC ferric chloride model. 40 Inhibitors targeting the intrinsic pathway have been assessed for their ability to limit venous thrombosis in animal models (Table 2 ). An anti-FVIII antibody, LE2E9, potently inhibited thrombus formation in wild-type and FVIII humanized mice subject to the St Thomas' model. 31 Interestingly, in contrast to the severe bleeding phenotype of FVIII-deficient mice, bleeding in LE2E9-treated mice was comparable to that of controls. 31 In a rabbit femoral vein thread-induced model, a blocking antibody that binds to the enzymatic pocket of FXIa, referred to as DEF, reduced thrombus formation in a dosedependent manner. 47 Importantly, DEF was not associated with increased bleeding in a rabbit cuticle model. 47 A pair of anti-FXI antibodies, αFXI-175 and αFXI-203, have also been found to significantly prolong time to occlusion in the IVC ferric chloride model. 46 An ASO targeting FXI robustly inhibited thrombus formation in the IVC ferric chloride, mesenteric vein ferric chloride, and St Thomas' models without an associated bleeding phenotype. 51 ASOs targeting FXII and PKK also demonstrated reduced thrombus formation in the IVC ferric chloride models and St Thomas' without affecting bleeding. 52 Interestingly, in this study, knockdown of PKK resulted in a gradual dose-dependent reduction in thrombus formation in the St Thomas' model. In contrast, FXII knockdown demonstrated a steep dose-response with significant reduction in thrombus formation only observed at FXII ASO doses that reduced the plasma FXII concentration by >80%. 52 This suggests that only relatively small amounts of FXII are required to promote venous thrombosis in this model. The FXIIa inhibitor, Phe-Pro-Arg-chloromethylketone, was also reported to reduce thrombus formation in the IVC stenosis model. 36 Similarly, rHA-infestin 4 markedly reduced the formation of occlusive thrombi in the IVC ferric chloride model. 57 A tick derived protein Ixodes ricinus contact phase inhibitor has been identified as a broad-acting antagonist against FXIa, FXIIa, and αKK. 60 Ixodes ricinus contact phase inhibitor administration reduced thrombus formation in both the rat IVC stasis and mouse IVC ferric chloride models at doses that did not affect bleeding after tail vein transection.
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Primate Models
In an attempt to bridge the gap between rodents and humans, numerous intrinsic pathway inhibitors have been assessed in a baboon model of graft thrombosis. In this model, a collagencoated arteriovenous shunt serves as a thrombogenic surface with propagation facilitated by the presence of an uncoated region or expansion chamber. 53 Initiation of thrombus formation in response to collagen is intended to simulate exposure of the subendothelial matrix after arterial injury. In this model, inhibition of FXI by a goat anti-human FXI antibody and mouse anti-human FXI clone O1A6 (also referred to as aXIMab) reduced thrombus formation. [71] [72] [73] FXI ASOs also inhibited thrombus formation in this model. 73 Encouragingly, inhibition of FXIIa-mediated activation of FXI with the anti-FXI antibody 14E11 and FXII activation with the anti-FXII antibody 15H8 also reduced thrombus formation. 33, 53 It is important to note, however, that the FXI-targeting antibody O1A6 demonstrated more potent inhibition of platelet accumulation in the collagen-coated segment of the graft than either 14E11 or 15H8. This suggests that targeting of FXIa-mediated activation of FIX may be more effective than targeting FXIIa-mediated activation of FXI in preventing thrombosis on collagen surfaces.
Epidemiology
Evidence from rodent models of arterial and venous thrombosis suggests that targeting of FXII may offer stronger protection against thrombosis than FXI. 33, 36 However, there seems to be discordance between findings from rodent models and observations made in human studies. Patients with severe FXI have a reduced risk of stroke and VTE (venous thromboembolism). [74] [75] [76] Conversely, elevated plasma FXI antigen levels is associated with an increased risk of stroke and VTE. [77] [78] [79] The involvement of FXII in the pathogenesis of thrombotic disorders, however, is not well established. Studies of patients with FXII deficiency are limited but have not demonstrated protection against thrombotic events. 80 Similarly, plasma FXII antigen levels have not been associated with changes in risk of stroke, myocardial infarction, and VTE. 78, 79 
Clinical Studies
Therapies targeting components of the intrinsic pathway found to be effective in inhibiting thrombosis in preclinical studies have begun to be assessed in the clinical setting. 81 Studies to date have primarily focused on FXI inhibitors likely because of the available supporting human levels data for the role of this factor in thrombotic disorders. An FXI-targeting ASO developed by Ionis Pharmaceuticals, IONIS-416858, has successfully completed Phase I and II clinical trials. 82, 83 In the phase I trial doses sufficient to lower FXI plasma levels by ≈80% were well tolerated with no evidence of excessive bleeding or agent associated toxicity. 82 In a phase 2 trial, prophylactic treatment with IONIS-416858 was compared with enoxaparin for the ability to prevent VTE in patients undergoing total knee arthroplasty. 83 Importantly, the higher 300 mg dose of FXI ASO was superior to enoxaparin in preventing VTE with less major or clinically relevant nonmajor bleeding. 83 FXIa-targeted agents, including the anti-FXIa antibody BAY1213790 (http://www.clinicaltrials.gov. Unique identifier: NCT03276143) and the small molecule FXIa inhibitor BMS-962212, are also currently undergoing clinical evaluation. 84 Additional inhibitors of the contact pathway have been developed for the treatment of hereditary angioedema. The PKK inhibitor ecallantide has completed phase III trials and is approved for the treatment of acute attacks, with other agents currently undergoing clinical assessment. [85] [86] [87] It is interesting to consider whether PKK inhibitors developed for treatment of hereditary angioedema could find additional utility as antithrombotic agents.
Conclusions
Studies of intrinsic pathway knockouts highlight the critical contribution of this pathway to the pathogenesis of arterial and venous thrombosis. Numerous intrinsic pathway inhibitors have been developed that provide robust antithrombotic activity in animal models. Development of agents targeting FXI and FXII is of particular interest because of the limited contribution of these factors toward hemostasis. It remains to be determined if this approach can deliver a new class of clinically safe and effective anticoagulants.
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